Which has stronger earnings and valuation, ILMN or QGEN?

Illumina has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Illumina $4.34B 7.59 $850M $5.36 40.71 Qiagen $2.09B 4.28 $424.88M $1.95 22.24

Is ILMN or QGEN more profitable?

Qiagen has a net margin of 19.49% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Qiagen's return on equity. Company Net Margins Return on Equity Return on Assets Illumina 18.36% 29.84% 12.17% Qiagen 19.49% 14.47% 8.34%

Does the media favor ILMN or QGEN?

In the previous week, Illumina had 34 more articles in the media than Qiagen. MarketBeat recorded 39 mentions for Illumina and 5 mentions for Qiagen. Illumina's average media sentiment score of 0.85 beat Qiagen's score of 0.63 indicating that Illumina is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 22 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive Qiagen 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TMO or ILMN?

In the previous week, Illumina had 6 more articles in the media than Thermo Fisher Scientific. MarketBeat recorded 39 mentions for Illumina and 33 mentions for Thermo Fisher Scientific. Thermo Fisher Scientific's average media sentiment score of 1.30 beat Illumina's score of 0.85 indicating that Thermo Fisher Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Thermo Fisher Scientific 25 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Illumina 22 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive

Does the media favor A or ILMN?

In the previous week, Illumina had 24 more articles in the media than Agilent Technologies. MarketBeat recorded 39 mentions for Illumina and 15 mentions for Agilent Technologies. Illumina's average media sentiment score of 0.85 beat Agilent Technologies' score of 0.80 indicating that Illumina is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 5 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Illumina 22 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive

Which has higher valuation & earnings, ILMN or IQV?

IQVIA has higher revenue and earnings than Illumina. IQVIA is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Illumina $4.34B 7.59 $850M $5.36 40.71 IQVIA $16.31B 2.70 $1.36B $8.06 33.17

Is ILMN or IQV more profitable?

Illumina has a net margin of 18.36% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Illumina's return on equity. Company Net Margins Return on Equity Return on Assets Illumina 18.36% 29.84% 12.17% IQVIA 8.10% 30.25% 6.54%

Does the media refer more to ILMN or IQV?

In the previous week, Illumina had 20 more articles in the media than IQVIA. MarketBeat recorded 39 mentions for Illumina and 19 mentions for IQVIA. IQVIA's average media sentiment score of 1.22 beat Illumina's score of 0.85 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 22 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive IQVIA 16 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ILMN or WAT?

Illumina has higher revenue and earnings than Waters. Illumina is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Illumina $4.34B 7.59 $850M $5.36 40.71 Waters $3.17B 12.71 $642.63M $4.01 102.09

Is ILMN or WAT more profitable?

Illumina has a net margin of 18.36% compared to Waters' net margin of 3.58%. Illumina's return on equity of 29.84% beat Waters' return on equity. Company Net Margins Return on Equity Return on Assets Illumina 18.36% 29.84% 12.17% Waters 3.58% 11.27% 6.73%

Does the media prefer ILMN or WAT?

In the previous week, Illumina had 19 more articles in the media than Waters. MarketBeat recorded 39 mentions for Illumina and 20 mentions for Waters. Illumina's average media sentiment score of 0.85 beat Waters' score of 0.85 indicating that Illumina is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 22 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive Waters 12 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Illumina (ILMN) Competitors

$218.22 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

ILMN vs. QGEN, TMO, A, IQV, and WAT

Should you buy Illumina stock or one of its competitors? Illumina's main competitors and comparable companies include Qiagen (QGEN), Thermo Fisher Scientific (TMO), Agilent Technologies (A), IQVIA (IQV), and Waters (WAT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Illumina compare to Qiagen?

Illumina (NASDAQ:ILMN) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Illumina has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Illumina currently has a consensus price target of $191.31, suggesting a potential downside of 12.33%. Qiagen has a consensus price target of $43.93, suggesting a potential upside of 1.30%. Given Qiagen's stronger consensus rating and higher possible upside, analysts clearly believe Qiagen is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	7 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.39
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43

Illumina has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	7.59	$850M	$5.36	40.71
Qiagen	$2.09B	4.28	$424.88M	$1.95	22.24

89.4% of Illumina shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 2.9% of Illumina shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Illumina had 34 more articles in the media than Qiagen. MarketBeat recorded 39 mentions for Illumina and 5 mentions for Qiagen. Illumina's average media sentiment score of 0.85 beat Qiagen's score of 0.63 indicating that Illumina is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	22 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive
Qiagen	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.49% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
Qiagen	19.49%	14.47%	8.34%

Summary

Illumina beats Qiagen on 12 of the 17 factors compared between the two stocks.

How does Illumina compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Illumina (NASDAQ:ILMN) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

In the previous week, Illumina had 6 more articles in the media than Thermo Fisher Scientific. MarketBeat recorded 39 mentions for Illumina and 33 mentions for Thermo Fisher Scientific. Thermo Fisher Scientific's average media sentiment score of 1.30 beat Illumina's score of 0.85 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	25 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Illumina	22 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 2.9% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Thermo Fisher Scientific presently has a consensus price target of $619.41, suggesting a potential upside of 1.09%. Illumina has a consensus price target of $191.31, suggesting a potential downside of 12.33%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, equities analysts clearly believe Thermo Fisher Scientific is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Illumina	2 Sell rating(s)	7 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.39

Illumina has a net margin of 18.36% compared to Thermo Fisher Scientific's net margin of 15.04%. Illumina's return on equity of 29.84% beat Thermo Fisher Scientific's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.04%	17.09%	8.12%
Illumina	18.36%	29.84%	12.17%

Thermo Fisher Scientific has higher revenue and earnings than Illumina. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56B	5.08	$6.70B	$18.59	32.96
Illumina	$4.34B	7.59	$850M	$5.36	40.71

Thermo Fisher Scientific has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Illumina has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market.

Summary

Illumina beats Thermo Fisher Scientific on 9 of the 17 factors compared between the two stocks.

How does Illumina compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Illumina (NASDAQ:ILMN) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

89.4% of Illumina shares are held by institutional investors. 2.9% of Illumina shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Illumina had 24 more articles in the media than Agilent Technologies. MarketBeat recorded 39 mentions for Illumina and 15 mentions for Agilent Technologies. Illumina's average media sentiment score of 0.85 beat Agilent Technologies' score of 0.80 indicating that Illumina is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	5 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Illumina	22 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive

Agilent Technologies has higher revenue and earnings than Illumina. Agilent Technologies is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	6.11	$1.30B	$5.08	29.65
Illumina	$4.34B	7.59	$850M	$5.36	40.71

Agilent Technologies currently has a consensus price target of $170.33, indicating a potential upside of 13.10%. Illumina has a consensus price target of $191.31, indicating a potential downside of 12.33%. Given Agilent Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe Agilent Technologies is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.85
Illumina	2 Sell rating(s)	7 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.39

Agilent Technologies has a net margin of 19.53% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.53%	24.45%	13.09%
Illumina	18.36%	29.84%	12.17%

Agilent Technologies has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Illumina has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Summary

Illumina beats Agilent Technologies on 9 of the 17 factors compared between the two stocks.

How does Illumina compare to IQVIA?

Illumina (NASDAQ:ILMN) and IQVIA (NYSE:IQV) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Illumina has a net margin of 18.36% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Illumina's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
IQVIA	8.10%	30.25%	6.54%

Illumina presently has a consensus price target of $191.31, suggesting a potential downside of 12.33%. IQVIA has a consensus price target of $243.63, suggesting a potential downside of 8.87%. Given IQVIA's stronger consensus rating and higher possible upside, analysts plainly believe IQVIA is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	7 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.39
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Illumina had 20 more articles in the media than IQVIA. MarketBeat recorded 39 mentions for Illumina and 19 mentions for IQVIA. IQVIA's average media sentiment score of 1.22 beat Illumina's score of 0.85 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	22 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive
IQVIA	16 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.4% of Illumina shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 2.9% of Illumina shares are owned by company insiders. Comparatively, 1.7% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

IQVIA has higher revenue and earnings than Illumina. IQVIA is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	7.59	$850M	$5.36	40.71
IQVIA	$16.31B	2.70	$1.36B	$8.06	33.17

Illumina has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Summary

IQVIA beats Illumina on 10 of the 17 factors compared between the two stocks.

How does Illumina compare to Waters?

Illumina (NASDAQ:ILMN) and Waters (NYSE:WAT) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Illumina has a net margin of 18.36% compared to Waters' net margin of 3.58%. Illumina's return on equity of 29.84% beat Waters' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
Waters	3.58%	11.27%	6.73%

Illumina has higher revenue and earnings than Waters. Illumina is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	7.59	$850M	$5.36	40.71
Waters	$3.17B	12.71	$642.63M	$4.01	102.09

In the previous week, Illumina had 19 more articles in the media than Waters. MarketBeat recorded 39 mentions for Illumina and 20 mentions for Waters. Illumina's average media sentiment score of 0.85 beat Waters' score of 0.85 indicating that Illumina is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	22 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive
Waters	12 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

89.4% of Illumina shares are held by institutional investors. Comparatively, 94.0% of Waters shares are held by institutional investors. 2.9% of Illumina shares are held by company insiders. Comparatively, 0.3% of Waters shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Illumina has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Waters has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Illumina currently has a consensus price target of $191.31, suggesting a potential downside of 12.33%. Waters has a consensus price target of $424.35, suggesting a potential upside of 3.65%. Given Waters' stronger consensus rating and higher possible upside, analysts plainly believe Waters is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	7 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.39
Waters	0 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	2.80

Summary

Illumina beats Waters on 10 of the 17 factors compared between the two stocks.

Get Illumina News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ILMN vs. The Competition

Export

Metric	Illumina	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.95B	$9.93B	$7.21B	$12.89B
Dividend Yield	N/A	1.47%	2.54%	9.13%
P/E Ratio	40.71	65.01	273.84	25.45
Price / Sales	7.59	109.64	625.55	100.83
Price / Cash	32.50	26.85	28.92	35.62
Price / Book	12.25	5.38	11.01	6.39
Net Income	$850M	$56.67B	$3.49B	$358.69M
7 Day Performance	2.15%	-0.76%	1.63%	0.22%
1 Month Performance	16.10%	1.51%	4.42%	-0.10%
1 Year Performance	120.58%	24.09%	24.21%	14.04%

Illumina Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ILMN Illumina	2.0718 of 5 stars	$218.22 flat	$191.31 -12.3%	+120.6%	$32.95B	$4.34B	40.71	8,650	Insider Trade
QGEN Qiagen	2.5968 of 5 stars	$43.74 +4.7%	$43.93 +0.4%	-13.3%	$8.61B	$2.09B	22.41	5,654
TMO Thermo Fisher Scientific	4.2303 of 5 stars	$627.96 -0.1%	$619.41 -1.4%	+24.5%	$232.47B	$44.56B	33.78	125,000	Positive News
A Agilent Technologies	4.7846 of 5 stars	$154.81 +0.9%	$160.24 +3.5%	+17.0%	$43.33B	$6.95B	31.09	18,100
IQV IQVIA	3.6965 of 5 stars	$259.97 -0.1%	$241.88 -7.0%	+42.4%	$42.84B	$16.31B	32.25	93,000	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ILMN) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Illumina (ILMN) Competitors